8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  June 25, 2013

Echo Therapeutics, Inc.

 (Exact name of Company as specified in its charter)

Delaware	000-23017	41-1649949
(State or other jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
8 Penn Center 1628 JFK Blvd., Suite 300 Philadelphia, PA		19103
(Address of principal executive offices)		(Zip Code)

Company’s telephone number, including area code: (215) 717-4100

 (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.   Other Events.

On June 25, 2013, the Company received a letter from The Nasdaq Stock Market (“NASDAQ”) stating that the Company had regained compliance with NASDAQ’s Marketplace Rule 5450(a)(2) because the bid price of the Company’s common stock closed at or above the required minimum $1.00 per share for twelve consecutive business days.  A copy of NASDAQ’s letter is attached as Exhibit 99.1 to this report.  On June 26, 2014, the Company issued a press release announcing the receipt of NASDAQ’s letter.  A copy of the press release is attached as Exhibit 99.2 to this report.

Item 9.01.   Financial Statements and Exhibits.

The Exhibits listed in the Exhibit Index immediately preceding such Exhibits are filed with or incorporated by reference in this report.

SIGNATURES

              Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ECHO THERAPEUTICS, INC.
Dated: June 28, 2013	By:  /s/  Patrick T. Mooney
	Patrick T. Mooney
	President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Letter from NASDAQ to the Company dated June 25, 2013.
99.2	Press Release issued by the Company on June 26, 2013.

EX-99.1

Exhibit 99.1

By Electronic Delivery to: cschnittker@echotx.com; kburke@echotx.com; colimpio@echotx.com

June 25, 2013

Christopher P. Schnittker, CPA

Senior Vice President and Chief Financial Officer

Echo Therapeutics, Inc.

8 Penn Center

1628 JFK Blvd., Suite 300

Philadelphia, PA 19103

Re: Echo Therapeutics, Inc. (the “Company”) Nasdaq Security: Common Stock Nasdaq Symbol: ECTE

Dear Mr. Schnittker:

On March 19, 2013, Staff notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. Since then, Staff has determined that for the last 12 consecutive business days, from June 7, 2013 to June 24, 2013, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.

If you have any questions, please contact Rachel Scherr, Listing Analyst, at +1 301 978 8072.

Sincerely,

/s/ Randy Genau

Randy Genau

Director

Nasdaq Listing Qualifications

EX-99.2

Exhibit 99.2

Echo Therapeutics Regains Compliance with Nasdaq Listing Requirements

Philadelphia, PA – June 26, 2013 – Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it has been notified by the Nasdaq Stock Market (“Nasdaq”) that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.

As previously disclosed, on March 19, 2013, the Nasdaq Listing Qualifications department notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days and, as a result, the Company was not in compliance with Listing Rule 5550(a)(2).  The company was provided 180 calendar days, or until September 16, 2013, to regain compliance.

On June 25, 2013, Nasdaq notified the Company that the closing bid price of its common stock has been at $1.00 per share or greater for the last 12 consecutive business days.  Accordingly, Nasdaq confirmed that the Company has regained compliance with the minimum bid price rule and that the matter is now closed.

“We are very pleased to have regained compliance with the Nasdaq listing requirements.  We remain focused on increasing shareholder value by executing on several key clinical and regulatory milestones this year to bring the Symphony CGM System to market,” commented Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system.  Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care.  Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting.  Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements including, without limitation, the statement regarding our plan to execute on several key clinical and regulatory milestones this year, that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:

Christine H. Olimpio

Director, Investor Relations and Corporate Communications

(215) 717-4104

Connect With Us:

- Visit our website at www.echotx.com

- Follow us on Twitter at www.twitter.com/echotx

- Join us on Facebook at www.facebook.com/echotx